Pharma & Biotech
-
Amid Continued Financial Struggles, Warrington’s Windtree Therapeutics Shifts Focus
Following failed forays into real estate and crypto, Warrington-based Windtree Therapeutics is reinventing itself as a waste management and environmental services firm, writes John George for the Philadelphia Business Journal. This surprising pivot comes after the company’s struggle to find a partner for its drug candidate pipeline. “Capital is scarce out there, especially for cardiovascular…
-
CSL Laying Off 55 Vifor Employees at King of Prussia In 15 Percent Workforce Reduction
CSL is laying off 55 employees from Vifor subsidiary assigned to its King of Prussia office in a 15 percent workforce reduction announced in August, writes John George for the Philadelphia Business Journal. “Following a thorough assessment of our business needs and the broader economic environment, we have reorganized our field-based teams to support our…
-
Merck’s Oral Cholesterol Therapy Offers Easier Alternative to Injections
Merck, the pharmaceutical giant with multiple locations across Montco, is reporting success with a new oral cholesterol drug, according to Reuters. The drug, enlicitide decanoate, recently met its main goal in a late-stage trial by reducing LDL (bad cholesterol) levels, which is a major risk factor for heart disease. Merck anticipates patent losses for their…
-
Two Pharma Companies Partner to Open Dedicated OSD Form Suite in Sellersville
Piramal Pharma Solutions and NewAmsterdam Pharma Company will be opening a dedicated oral solid dosage form suite at Piramal’s facility in Sellersville. The Sellersville site is one of Piramal Pharma Solutions’ focused drug product facilities offering comprehensive development and manufacturing services for a variety of formulations, including various oral solid dosages. The new suite will…
-
Doylestown’s Pennsylvania Biotech Center Recruits Hepatitis C Cure Inventor
Michael J. Sofia, the inventor of the Hepatitis C cure, has joined the Pennsylvania Biotechnology Center in Doylestown, working towards a cure for Hepatitis B, writes John George for the Philadelphia Business Journal. Sofia will be the distinguished professor and principal investigator at the Bucks County biotech center, a life sciences incubator and educational hub…
-
Radnor-Based Avantor Shares Climb After Activist Investor Calls to Streamline or Sell Company
Avantor shares rose almost ten percent on Monday after activist investor Engine Capital Management pushed to either streamline operations or sell the Radnor-based chemical and lab gear maker, writes Joseph N. DiStefano for The Philadelphia Inquirer. The company’s stock had recently been trading at its lowest value since 2019 when it went public. By the…
-
Warrington’s Windtree Therapeutics Signs Cryptocurrency Deal Worth Up To $200M
After expanding into real estate and waste management in its search for new revenue opportunities to boost stock value, Warrington-based Windtree Therapeutics has entered a potential $200 million cryptocurrency deal, writes John George for the Philadelphia Business Journal. Stockpiling digital currencies to increase stock value is an emerging trend among public companies, including video game…
-
Wistar Institute Opens New HIV Cure and Viral Diseases Center
The Wistar Institute recently celebrated a ribbon cutting for the opening of its new HIV Cure and Viral Diseases Center. The vision for the center is to uncover the fundamental science that powers tomorrow’s cures for HIV and other viral diseases. The belief is that revealing how viruses work and how the immune system responds,…
-
Baby KJ Leaves CHOP for Return Home to Clifton Heights
A Clifton Heights baby treated for a life-threatening genetic disorder with a pioneering gene editing therapy is out of the hospital and back home, writes Aubrey Whelan for The Philadelphia Inquirer. Baby KJ left Children’s Hospital of Philadelphia Tuesday after 307 days. KJ Muldoon suffered from severe carbamoyl phosphate synthetase 1 deficiency, which prevents the…
-
Merck’s West Point Presence Remains Strong Amid Riverside Closure
As Merck moves forward with plans to close their Riverside facility, the company remains committed to its West Point location and other sites, writes Nathan Owens for Manufacturing Drive. The Riverside plant, which once employed 300 people, was originally slated to cease production in 2024. Merck hasn’t disclosed why the timeline was delayed but noted…
-
Malvern Medical Manufacturer Cleared for First-of-Its-Kind Alzheimer’s Blood Test
A first-of-its-kind blood test developed by Malvern-based Fujirebio Diagnostics to help diagnose Alzheimer’s disease has received clearance from the U.S. Food and Drug Administration, writes Courtenay Harris Bond for PhillyVoice. The blood test detects the abnormal protein brain deposits associated with the disease. It is intended for individuals aged 55 and older who are already…
-
Clifton Heights Baby Doing Well After Gene-Editing Treatment
KJ Muldoon of Clifton Heights, once a critically ill baby, is “growing and thriving” after a custom-made gene editing treatment, according to gene therapy expert Dr. Rebecca Ahrens-Nicklas. The 9-1/2-month-old is among the first to have a genetic disease treated through personalized gene editing, according to an Associated Press article appearing in The Keystone. A…
-
Merck Expands Biomanufacturing with Staggering Investment in Wilmington
Merck, the Pharma giant with operations in Lansdale, announced on Tuesday that it will build a $1 billion “biologics center of excellence” in Wilmington, writes John George and Paul Schwedelson for Philadelphia Business Journal. The new facility, dubbed Merck Wilmington Biotech, will anchor the Chestnut Run Innovation & Science Park, a sprawling campus developed by…
-
Avantor in Radnor Is Losing Longtime CEO Michael Stubblefield
Radnor life sciences products company Avantor is losing its CEO Michael Stubblefield, writes John George for the Philadelphia Business Journal. It was announced Friday that Stubblefield is stepping down after serving as CEO since May 2014. He will stay in the role until a successor is found. He will also be retained until February 2026…
-
Federal Funding Gap Hits Horsham Lab Tracking Emerging Drug Threats
Horsham’s Center for Forensic Science Research and Education has laid off 12 employees due to delays in federal grant funding, writes John George for the Philadelphia Business Journal. The nonprofit had expected $2.1 million from the Departments of Justice and State to support key programs this year, but none of the funds have arrived. Chairman…
-
Federal Funding Gap Hits Horsham Lab Tracking Emerging Drug Threats
Horsham’s Center for Forensic Science Research and Education has laid off 12 employees due to delays in federal grant funding, writes John George for the Philadelphia Business Journal. The nonprofit had expected $2.1 million from the Departments of Justice and State to support key programs this year, but none of the funds have arrived. Chairman…
-
To Prep for First Product Launch, Exton’s Lungpacer Medical Doubles Workforce
Lungpacer Medical, headquartered in Canada with main operations in Exton, is raising funds and nearly doubling its workforce to support the commercial launch of its first product, which received Food and Drug Administration approval at the end of last year, writes John George for the Philadelphia Business Journal. According to Lungpacer CEO Doug Evans, the…
-
Iovance Biotherapeutics Likely to Add Hundreds of New Jobs At Philadelphia Navy Yard
As part of an effort to increase its cell therapy manufacturing, Iovance Biotherapeutics is planning to add hundreds of new jobs at its manufacturing site at the Philadelphia Navy Yard, writes John George for the Philadelphia Business Journal. This would double the company’s current production capacity. According to Iovance’s interim CEO Fred Vogt, the expansion…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
